Sugi Predict

Sugi Predict / Targets / MAP3K7

MAP3K7

Mitogen-activated protein kinase kinase kinase 7 · O43318 · MAP3K7 on Sugi Atlas →

59,857 patent compounds predicted against MAP3K7, 45,300 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL93523 SCHEMBL93523 0.74 5/20
SCHEMBL93524 SCHEMBL93524 0.57 5/20
SCHEMBL93511 SCHEMBL93511 0.58 3/20
SCHEMBL141930 SCHEMBL141930 0.90 2/20
SCHEMBL142206 SCHEMBL142206 0.85 2/20
SCHEMBL93510 SCHEMBL93510 0.77 2/20
SCHEMBL141676 SCHEMBL141676 0.69 2/20
SCHEMBL141372 SCHEMBL141372 0.68 2/20
SCHEMBL141123 SCHEMBL141123 0.55 2/20
SCHEMBL142205 SCHEMBL142205 0.49 2/20
SCHEMBL46725 SCHEMBL46725 0.44 2/20
SCHEMBL46985 SCHEMBL46985 0.42 2/20
SCHEMBL46746 SCHEMBL46746 0.41 2/20
SCHEMBL39856 SCHEMBL39856 0.38 2/20
SCHEMBL67059 SCHEMBL67059 0.37 2/20
Adenosine Adenosine (SCHEMBL731) 1.00 1/20
Canertinib Canertinib (SCHEMBL54837) 1.00 1/20
Adenosine Adenosine (SCHEMBL63363) 1.00 1/20
Quizartinib Quizartinib (SCHEMBL72923) 1.00 1/20
Pha-665752 Pha-665752 (SCHEMBL93654) 1.00 1/20

Clinical trials — most relevant to MAP3K7 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma PHASE4UNKNOWN
Molecular Mechanisms of Type 2 Diabetes Mellitus PHASE4COMPLETED
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma PHASE1/PHASE2COMPLETED
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma PHASE1/PHASE2COMPLETED
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations PHASE2RECRUITING
Dabrafenib + Trametinib + PDR001 In Colorectal Cancer PHASE2UNKNOWN
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations PHASE2ACTIVE_NOT_RECRUITING
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. PHASE2UNKNOWN
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer PHASE2COMPLETED
MEK162 for Patients With RAS/RAF/MEK Activated Tumors PHASE2COMPLETED
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer PHASE2COMPLETED
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer PHASE2COMPLETED
Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia PHASE2COMPLETED
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma PHASE2COMPLETED
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma PHASE1/PHASE2SUSPENDED
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 PHASE1COMPLETED
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors PHASE1ACTIVE_NOT_RECRUITING
Nilotinib in Huntington's Disease PHASE1UNKNOWN
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer PHASE1COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 PHASE1WITHDRAWN
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo nanUNKNOWN
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
Molecular Analysis of Thoracic Malignancies nanENROLLING_BY_INVITATION
Clinical Genetics Branch Eligibility Screening Survey nanNOT_YET_RECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection. nanCOMPLETED
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment nanACTIVE_NOT_RECRUITING
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a MAP3K7 binder may also engage these)

ProteinNameSimilarity
Q62073 — 1.000 Q62073 →
A2VDU3 — 1.000 A2VDU3 →
P0C8E4 — 1.000 P0C8E4 →
Q5RFL3 — 1.000 Q5RFL3 →
P34152 — 0.990 P34152 →
PTK2 Focal adhesion kinase 1 0.988 landscape →
O35346 — 0.988 O35346 →
Q61083 — 0.987 Q61083 →
MAP3K3 Mitogen-activated protein kinase kinase kinase 3 0.987 landscape →
Q00944 — 0.987 Q00944 →
Q61084 — 0.987 Q61084 →
Q8BYW1 — 0.987 Q8BYW1 →
P34908 — 0.986 P34908 →
Q5U2Z7 — 0.986 Q5U2Z7 →
A7E3S4 — 0.985 A7E3S4 →
E9PUQ8 — 0.985 E9PUQ8 →
Q61UC4 — 0.984 Q61UC4 →
P09560 — 0.984 P09560 →
Q5R5M7 — 0.984 Q5R5M7 →
MAP3K2 Mitogen-activated protein kinase kinase kinase 2 0.984 landscape →
A1Z7T0 — 0.984 A1Z7T0 →
Q91738 — 0.983 Q91738 →
KSR2 Kinase suppressor of Ras 2 0.983 landscape →
P11345 — 0.983 P11345 →
PTPN14 Tyrosine-protein phosphatase non-receptor type 14 0.983 landscape →
Q3UVC0 — 0.983 Q3UVC0 →
Q8C4V1 — 0.982 Q8C4V1 →
Q960C5 — 0.982 Q960C5 →
Q69Z98 — 0.982 Q69Z98 →
Q8AXB4 — 0.982 Q8AXB4 →